Muses Labs Overview
- Founded
- 2013
- Status
- Private
- Employees
- 4
- Latest Deal Type
- Series B
- Latest Deal Amount
- $2.06M
- Investors
- 1
Muses Labs General Information
Description
Developer of a medical platform designed to provide prevention and recovery for Alzheimer's disease. The company's platform provides a therapy that targets all underlying causes of Alzheimer's with a goal to return individuals to normal cognitive function, enabling patients to lead normal lives again.
Contact Information
Website
www.museslabs.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Healthcare Services
Other Industries
Other Healthcare Technology Systems
Other Healthcare
Primary Office
- 9660 Falls of Neuse Road
- Suite 138-146
- Raleigh, NC 27615
- United States
+1 (984) 000-0000
Muses Labs Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series B) | 06-Jul-2017 | $2.06M | 00.000 | 000.00 | Completed | Generating Revenue |
| 1. Early Stage VC (Series A) | 01-Jul-2015 | 00000 | 00000 | 00.00 | Completed | Generating Revenue |
Muses Labs Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 00.000 |
| Series A | 0,000,000 | 00.000000 | 00 | 00.00 | 00.00 | 00 | 00.00 | 0.000 |
Muses Labs Patents
Muses Labs Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10460842-B1 | Interactive and analytical system that provides a dynamic tool for therapies to prevent and cure dementia-related diseases | Active | 29-Jan-2014 | 000000000 | 0 |
| US-20150213232-A1 | Interactive and analytical system that provides a dynamic tool for therapies to prevent and cure dementia-related diseases | Abandoned | 29-Jan-2014 | 000000000 | 0 |
Muses Labs Executive Team (7)
Muses Labs Board Members (4)
| Name | Representing | Role | Since |
|---|---|---|---|
| John Ryals | Muses Labs | Board Member | 000 0000 |
| John Walker Ph.D | Muses Labs | Co-Founder, Chief Technology Officer & Board Member | 000 0000 |
| Vern Davenport | Muses Labs | Board Member | 000 0000 |
| Vikas Chandra | Muses Labs | Chief Executive Officer, President & Board Member | 000 0000 |
Muses Labs Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialMuses Labs Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| 180 Degree Capital | Hedge Fund | Minority | 000 0000 | 000000 0 |